UTHR Straddle Strategy
UTHR (United Therapeutics Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
UTHR (United Therapeutics Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $24.60B, a trailing P/E of 19.58, a beta of 0.60 versus the broader market, a 52-week range of 272.12-609.35, average daily share volume of 559K, a public-listing history dating back to 1999, approximately 1K full-time employees. These structural characteristics shape how UTHR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.60 indicates UTHR has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on UTHR?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current UTHR snapshot
As of May 15, 2026, spot at $567.93, ATM IV 32.70%, IV rank 15.85%, expected move 9.37%. The straddle on UTHR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on UTHR specifically: UTHR IV at 32.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a UTHR straddle, with a market-implied 1-standard-deviation move of approximately 9.37% (roughly $53.24 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated UTHR expiries trade a higher absolute premium for lower per-day decay. Position sizing on UTHR should anchor to the underlying notional of $567.93 per share and to the trader's directional view on UTHR stock.
UTHR straddle setup
The UTHR straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With UTHR near $567.93, the first option leg uses a $570.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed UTHR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 UTHR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $570.00 | $23.05 |
| Buy 1 | Put | $570.00 | $22.15 |
UTHR straddle risk and reward
- Net Premium / Debit
- -$4,520.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$4,441.11
- Breakeven(s)
- $524.80, $615.20
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
UTHR straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on UTHR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$52,479.00 |
| $125.58 | -77.9% | +$39,921.86 |
| $251.15 | -55.8% | +$27,364.73 |
| $376.72 | -33.7% | +$14,807.59 |
| $502.30 | -11.6% | +$2,250.46 |
| $627.87 | +10.6% | +$1,266.68 |
| $753.44 | +32.7% | +$13,823.81 |
| $879.01 | +54.8% | +$26,380.95 |
| $1,004.58 | +76.9% | +$38,938.09 |
| $1,130.15 | +99.0% | +$51,495.22 |
When traders use straddle on UTHR
Straddles on UTHR are pure-volatility plays that profit from large moves in either direction; traders typically buy UTHR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
UTHR thesis for this straddle
The market-implied 1-standard-deviation range for UTHR extends from approximately $514.69 on the downside to $621.17 on the upside. A UTHR long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current UTHR IV rank near 15.85% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on UTHR at 32.70%. As a Healthcare name, UTHR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to UTHR-specific events.
UTHR straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. UTHR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move UTHR alongside the broader basket even when UTHR-specific fundamentals are unchanged. Always rebuild the position from current UTHR chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on UTHR?
- A straddle on UTHR is the straddle strategy applied to UTHR (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With UTHR stock trading near $567.93, the strikes shown on this page are snapped to the nearest listed UTHR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are UTHR straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the UTHR straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 32.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$4,441.11 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a UTHR straddle?
- The breakeven for the UTHR straddle priced on this page is roughly $524.80 and $615.20 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current UTHR market-implied 1-standard-deviation expected move is approximately 9.37%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on UTHR?
- Straddles on UTHR are pure-volatility plays that profit from large moves in either direction; traders typically buy UTHR straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current UTHR implied volatility affect this straddle?
- UTHR ATM IV is at 32.70% with IV rank near 15.85%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.